文献速递角膜与眼表疾病眼整形与眼眶

培养口腔黏膜上皮移植用于慢性瘢痕性疾病穹窿重建的长期结果

Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases.
PubMed 文献 · Br J Ophthalmol · 2021-05-18

回顾性队列研究纳入15例患者16眼,评估培养口腔黏膜上皮移植(COMET)用于慢性瘢痕性疾病穹窿重建的长期效果,平均随访102.1±46.0个月。术后5年总体穹窿重建成功概率为79.6%±10.7%,热/化学伤为100%、眼瘢痕性类天疱疮(OCP)为53.3%±24.8%(p=0.53)。术后24周无疾病复发组3年成功概率显著高于复发组(100% vs 33.3%±27.2%,p=0.0073)。

要点

  • COMET对慢性瘢痕性疾病的睑球粘连松解和长期穹窿重建安全有效。
  • 术后5年总体成功概率79.6%±10.7%,不同基础疾病间存在差异。
  • 术后24周眼表外观无复发可预测长期手术成功。

核心结论

  • COMET对慢性瘢痕性眼病的睑球粘连松解及长期穹窿重建安全有效。
  • 5年成功概率因基础疾病不同而异,术后24周眼表外观是预测长期结局的因素。

研究设计与样本

  • 回顾性队列研究,纳入2002年6月至2008年12月间接受COMET的15例患者16眼。
  • 平均术后随访102.1±46.0个月(范围32-183个月)。
  • 疾病包括眼瘢痕性类天疱疮5眼、热/化学伤3眼、其他慢性病7眼(复发性翼状胬肉2眼、Stevens-Johnson综合征1眼、移植物抗宿主病1眼)。

主要发现

  • 术后5年总体穹窿重建成功概率为79.6%±10.7%。
  • 热/化学伤5年成功概率100%,OCP为53.3%±24.8%(p=0.53,log-rank检验)。
  • 术后24周无疾病复发组(13眼)3年成功概率100%,复发组(3眼)为33.3%±27.2%(p=0.0073,log-rank检验)。

临床怎么用

  • COMET可用于慢性瘢痕性疾病患者的睑球粘连松解和穹窿重建。
  • 术后24周眼表外观无复发提示长期预后较好,可据此进行随访管理。

局限性

  • 回顾性设计,样本量小(16眼),随访时间范围较大(32-183个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To investigate the long-term outcomes of cultivated oral mucosal epithelial transplantation (COMET) for fornix reconstruction in eyes with chronic cicatrising disease. METHODS: This retrospective cohort study involved 16 eyes of 15 patients who underwent COMET for symblepharon release and fornix reconstruction between June 2002 and December 2008. The mean postoperative follow-up period was 102.1±46.0 months (range: 32-183 months). The treated cicatrising disorders included ocular cicatricial pemphigoid (OCP, five eyes), thermal/chemical injury (three eyes) and other chronic diseases (seven eyes; including recurrent pterygium (two eyes), Stevens-Johnson syndrome (one eye) and graft-versus-host disease (one eye)). Ocular-surface appearance was evaluated before surgery, at 1, 4, 12 and 24 weeks postoperative, and then annually based on the previously reported scoring system. Main outcome measures included overall and disease-specific fornix-reconstruction success probabilities analysed by the Kaplan-Meier survival curve. Symblepharon/fornix-shortening recurrence at 24 weeks postoperative, and its relationship to long-term surgical success was also examined. RESULTS: At 5 years postoperative, the mean±SD overall fornix-reconstruction success probability was 79.6%±10.7%, and success probability for thermal/chemical injury and OCP was 100% and 53.3%±24.8%, respectively (p=0.53, log-rank test). The 3-year success probability was significantly higher in the no-disease-recurrence group at 24 weeks postoperative (13 eyes) than in the disease-recurrence group (three eyes) (100% and 33.3%±27.2%, respectively) (p=0.0073, log-rank test). CONCLUSION: COMET was found to be safe and effective for symblepharon release and long-term fornix reconstruction in eyes with chronic cicatrisation. Although the 5-year success probability differed depend on the underlying disease, ocular-surface appearance at 24 weeks postoperative is a factor for predicting long-term outcome.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Komai S, Inatomi T, Nakamura T, et al. Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases. Br J Ophthalmol. 2021. PMID: 34006509. doi:10.1136/bjophthalmol-2020-318547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。